BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, July 18, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Tango’s USP1 inhibitor TNG-348 cleared to enter clinic for BRCA1/2 mutant and other HRD+ cancers
To read the full story,
subscribe
or
sign in
.
Cancer
Tango’s USP1 inhibitor TNG-348 cleared to enter clinic for BRCA1/2 mutant and other HRD+ cancers
Sep. 7, 2023
Tango Therapeutics Inc. has received FDA clearance of its IND application for TNG-348...
BioWorld Science
Regulatory
Cancer
FDA
IND
